NeuBase Therapeutics Inc NBSE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.44
- Day Range
- $0.41–0.44
- 52-Week Range
- $0.39–4.80
- Bid/Ask
- $0.41 / $0.42
- Market Cap
- $1.55 Mil
- Volume/Avg
- 19,919 / 251,596
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 37
Valuation
|
Metric
|
NBSE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.18 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NBSE
Financial Strength
|
Metric
|
NBSE
|
|---|---|
Quick Ratio | 2.70 |
Current Ratio | 2.87 |
Interest Coverage | −2,824.19 |
Quick Ratio
NBSE
Profitability
|
Metric
|
NBSE
|
|---|---|
Return on Assets (Normalized) | −49.54% |
Return on Equity (Normalized) | −78.42% |
Return on Invested Capital (Normalized) | −60.13% |
Return on Assets
NBSE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pkqwgxgsml | Ylqdh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wzlklmrm | Whtvf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nqzwwqbn | Dlgdy | $97.8 Bil | |
MRNA
| Moderna Inc | Djxcylz | Qdl | $38.8 Bil | |
ARGX
| argenx SE ADR | Fvkcvxwzk | Bnvf | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Zkbcjjcyr | Nlmn | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Knvkyyvy | Bngjqs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jjqkprnq | Pjwnz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ccwsmrtr | Mwbjcs | $12.5 Bil | |
INCY
| Incyte Corp | Cpblzvx | Bkzrnr | $11.5 Bil |